FCF YoY
-83.32%
OCF YoY
-82.68%
Capex Change
+186.0K
FCF Conversion Δ
—
Free cash flow bridge for Climb Bio (CLYM) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: -$24.3M
FCF bridge breakdown for Climb Bio (CLYM) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | -$29.2M | — |
| Operating Cash Flow | -$24.1M | -99.2% |
| Capital Expenditure | -$186K | -0.8% |
| Free Cash Outflow | -$53.5M | — |
- Prior Free Cash Flow-$29.2M
- Operating Cash Flow-$24.1M
- Capital Expenditure-$186K
- Free Cash Outflow-$53.5M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.